<a href="https://laohu8.com/S/ESLA">Estrella Immunopharma</a> Partners with Baylor Research Institute to Expand STARLIGHT-1 Trial for B-cell Non-Hodgkin's Lymphoma
Estrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced a new partnership with the Baylor Research Institute, operating as Baylor Scott & White Research Institute in Dallas, Texas. This collaboration marks a significant development in Estrella's ongoing STARLIGHT-1 Phase I/II clinical trial, which is focused on evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). The partnership aims to expand the clinical footprint, accelerating the development of EB103 and enhancing patient access to this promising therapy. The Baylor Research Institute will serve as a new clinical site, now open for patient enrollment, furthering Estrella's mission to deliver safer and more effective treatments for NHL patients.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250605259623) on June 05, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。